Letters to the Editor [3]

Journal of International Medical Research

Volumn 36, Issue 1, 2008, Pages 204-208

  Farrell, Rachel ^a,b   Bendtzen, Klaus ^c,d   Bertolotto, Antonio ^e   Clark, Berwyn ^f   Comabella, Manuel ^g   Deisenhammer, Florian ^h   Fogdell Hahn, Anna ⁱ   Giovannoni, Gavin ^b   Hartung, Hans Peter ^j   Hemmer, Bernard ^k   Hillert, Jan ⁱ   Kappos, Ludwig ^l   Killestein, Joep ^l   Lindberg, Raija ^g   Montalban, Xavier ^m   Polman, Chris ^l   Sorensen, Per Soelberg ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c Rigshospitalet   (Denmark)

^d BioMonitor ApS   (Denmark)

^e SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^f Lab 21 Ltd   (United Kingdom)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h UNIVERSITY OF INNSBRUCK   (Austria)

ⁱ KAROLINSKA INSTITUTE   (Sweden)

^j HEINRICH HEINE UNIVERSITY   (Germany)

^k TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^l UNIVERSITY HOSPITAL BASEL   (Switzerland)

^m VU UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPYRETIC AGENT; BETA1 INTERFERON; BETA1A INTERFERON; NEUTRALIZING ANTIBODY;

DISEASE SEVERITY; DRUG EFFICACY; DRUG MANUFACTURE; DRUG STORAGE; FLU LIKE SYNDROME; GOOD MANUFACTURING PRACTICE; HUMAN; IMMUNOGENICITY; LETTER; LOW DRUG DOSE; MULTIPLE SCLEROSIS;

EID: 39149099154     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (10)

1. Goodin DS, Hurwitz B, Noronha A: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. J Int Med Res 2007; 35: 173-187.
2. Sorensen PS, Deisenhammer F, Duda P, et al: Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005; 12: 817-827.
3. Koch-Henriksen N, Sorensen PS, Christensen T, et al: A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology 2006; 66: 1056-1060.
4. Sorensen PS, Koch-Henriksen N, Ross C, et al: Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005; 65: 33-39.
5. Gneiss C, Reindl M, Lutterotti A, et al: Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity. Mult Scler 2004; 10: 507-510.
6. Francis GS, Rice GP, Alsop JC: Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005; 65: 48-55.
7. Kappos L, Clanet M, Sandberg-Wollheim M, et al: Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005; 65: 40-47.
8. Clanet M, Radue EW, Kappos L, et al: A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 2002; 59: 1507-1517.
9. Sorensen PS, Ross C, Clemmesen KM, et al: Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362: 1184-1191.
10. The IFNB Multiple Sclerosis Study Group: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-661.